Ardent Health Partners (ARDT) Stock Price, News & Analysis

Company Overview

Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.

Key Stats

• Today's Range: $14.74 to $15.00
• 50-Day Range: $11.61 to $15.40
• 52-Week Range: $11.31 to $20.72
• Volume: 209,075 shs
• Average Volume: 392,884 shs
• Market Capitalization: $2.13 billion
• P/E Ratio: 9.13
• Dividend Yield: N/A
• Price Target: $20.67
• Consensus Rating: Buy

Ardent Health Partners Stock Analysis - MarketRank™

Ardent Health Partners scored higher than 69% of companies evaluated by MarketBeat, and ranked 316th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Ardent Health Partners has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Ardent Health Partners has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 59.35%

Earnings Growth

Earnings for Ardent Health Partners are expected to grow by 59.35% in the coming year, from $1.23 to $1.96 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ardent Health Partners is 9.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.74.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ardent Health Partners is 9.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.01.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ARDT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ardent Health Partners does not currently pay a dividend.

Dividend Growth

Ardent Health Partners does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ARDT.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.24

News Sentiment

Ardent Health Partners has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Ardent Health Partners this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for ARDT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

3 people have added Ardent Health Partners to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ardent Health Partners insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.70% of the stock of Ardent Health Partners is held by insiders.

ARDT Stock Analysis - Frequently Asked Questions

How have ARDT shares performed this year?

Ardent Health Partners' stock was trading at $17.08 at the beginning of the year. Since then, ARDT stock has decreased by 12.9% and is now trading at $14.8850.
View the best growth stocks for 2025 here.

How were Ardent Health Partners' earnings last quarter?

Ardent Health Partners, LLC (NYSE:ARDT) announced its earnings results on Tuesday, May, 6th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.08. The firm had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.50 billion.
Read the conference call transcript.

When did Ardent Health Partners IPO?

Ardent Health Partners (ARDT) raised $192 million in an initial public offering on Thursday, July 18th 2024. The company issued 12,000,000 shares at a price of $16.00 per share.

Who are Ardent Health Partners' major shareholders?

Ardent Health Partners' top institutional shareholders include Vanguard Group Inc. (0.93%), Millennium Management LLC (0.67%), Allspring Global Investments Holdings LLC (0.57%) and Goldman Sachs Group Inc. (0.54%).

How do I buy shares of Ardent Health Partners?

Shares of ARDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ardent Health Partners own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ardent Health Partners investors own include Broadcom (AVGO), 4D Molecular Therapeutics (FDMT), Mirum Pharmaceuticals (MIRM), Micron Technology (MU), Uber Technologies (UBER), Advanced Micro Devices (AMD) and ASML (ASML).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 5/27/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: General medical & surgical hospitals
• Sub-Industry: Healthcare
• Current Symbol: NYSE:ARDT
• Previous Symbol: NYSE:ARDT
• CIK: 1756655
• Web: N/A
• Phone: (615) 296-3000
• Fax: N/A
• Employees: 24,200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $20.67
• High Stock Price Target: $25.00
• Low Stock Price Target: $18.00
• Potential Upside/Downside: +38.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 13 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 9.20
• Forward P/E Ratio: 12.18
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.78
• Current Ratio: 1.91
• Quick Ratio: 1.78

Sales & Book Value

• Annual Sales: $6.02 billion
• Price / Sales: 0.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 143,044,000
• Free Float: N/A
• Market Cap: $2.14 billion
• Optionable: Optionable
• Beta: N/A